LPTXLEAP THERAPEUTICS, INC.

Nasdaq leaptx.com


$ 2.90 $ -0.08 (-2.68 %)    

Thursday, 09-May-2024 15:56:50 EDT
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 2.91
$ 2.88
$ 0.00 x 0
$ 0.00 x 0
$ 2.87 - $ 2.90
$ 1.24 - $ 10.20
146,980
na
59.5M
$ 1.44
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-18-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-24-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-11-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-13-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-12-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-13-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-16-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-09-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 04-01-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
24 05-11-2018 03-31-2018 10-Q
25 02-23-2018 12-31-2017 10-K
26 11-13-2017 09-30-2017 10-Q
27 08-11-2017 06-30-2017 10-Q
28 05-12-2017 03-31-2017 10-Q
29 03-31-2017 12-31-2016 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

- SEC Filing

 baird-maintains-outperform-on-leap-therapeutics-lowers-price-target-to-9

Baird analyst Joel Beatty maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and lowers the price target from $11 t...

 hc-wainwright--co-reiterates-buy-on-leap-therapeutics-maintains-7-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:LPTX) with a Buy and maintains $...

 leap-therapeutics-q4-eps-046-beats-055-estimate-cash-balance-of-706m

Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0...

 leap-therapeutics-to-present-new-data-from-part-a-of-the-defiance-study-of-dkn-01-plus-bevacizumab-and-chemotherapy-in-colorectal-cancer-patients-at-the-2024-asco-gastrointestinal-cancers-symposium

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics,...

 why-flj-group-shares-are-trading-higher-by-around-96-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of FLJ Group Limited (NASDAQ: FLJ) shares jumped during Friday’s session after the company announced it entered into a d...

 mizuho-maintains-buy-on-leap-therapeutics-lowers-price-target-to-12

Mizuho analyst Mara Goldstein maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $20 to $12.

 raymond-james-maintains-outperform-on-leap-therapeutics-lowers-price-target-to-175

Raymond James analyst Steven Seedhouse maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and lowers the price targ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION